

**AMENDED CLAIMS +
STATEMENT UNDER ARTICLE 19(1)**

[Received by the International Bureau on 21 November 2005 (21.11.05);
original claims 1-28 amended; new claims 1-27 added (4 pages)]

1. A method of damaging target cells in a subject, the method comprising
5 administering to the subject
 - (1) a nucleic acid encoding a compound capable of converting a substrate to acetaldehyde, wherein said compound is an enzymatically active portion of alcohol dehydrogenase; and
 - (2) a substrate which is converted to acetaldehyde by the portion capable of converting said substrate to acetaldehyde;
10 wherein said substrate is ethanol.
- 15 2. A method according to claim 1 further comprising administering a component that is capable of inhibiting aldehyde dehydrogenase.
- 20 3. A method according to claim 2 wherein said component that is capable of inhibiting aldehyde dehydrogenase is Disulfiram.
- 25 4. A method according to any of claims 1 to 3 wherein the nucleic acid is in the form of a viral vector.
5. A method according to claim 4 wherein the viral vector is a DNA based viral vector.
6. A method according to claim 5 wherein the DNA based viral vector is an adenovirus derived viral vector.
- 30 7. A method according to any of claims 1 to 6 wherein the nucleic acid comprises a polynucleotide comprising a target cell-specific promoter operably linked to a polynucleotide encoding said alcohol dehydrogenase.

8. A method according to any preceding claim in which the portion of alcohol dehydrogenase converts the ethanol to acetaldehyde as a result of its enzymatic activity.
- 5
9. A method according to any of claims 4 to 8 wherein said vector comprises a target cell specific portion.
10. A method according to claim 9 in which the target cell specific portion comprises an antibody or part thereof.
11. A method according to claim 9 or claim 10 in which the target-cell specific portion is capable of selectively binding to a cell surface entity.
- 15
12. A method according to claim 11 in which the cell surface entity is a tumour-associated antigen.
13. A method according to any one of claims 9 to 12 in which the target cell specific portion comprises a liposome.
- 20
14. A method according to any one of claims 1 to 13 in which a radiation therapy is also administered to the subject.
- 25
15. A composition comprising a compound as defined in any of claims 1 to 13, wherein the portion of alcohol dehydrogenase is an enzymatically active portion of human alcohol dehydrogenase.
16. A composition according to claim 15 or claim 16 wherein said human alcohol dehydrogenase is alcohol dehydrogenase $\beta 2$.
- 30
17. A composition according to claim 15 or claim 16 further comprising a substance which is capable of inhibiting aldehyde dehydrogenase.

18. A composition according to claim 17 wherein said substance which is capable of inhibiting aldehyde dehydrogenase is Disulfiram.
- 5 19. A composition according to any of claims 15 to 18 further comprising a chemotherapeutic agent.
20. A composition according to any of claims 15 to 19 further comprising an immunosuppressive agent.
- 10 21. A composition according to any of claims 15 to 20 for use in medicine.
22. Use of a composition according to any of claims 15 to 20 in the manufacture of a medicament for the treatment of cancer.
- 15 23. Use of ethanol or pyruvate in the manufacture of a medicament for the treatment of cancer.
- 20 24. A therapeutic system or kit comprising a compound or system as defined in any of claims 1-13, or a composition as defined in any of claims 15 to 20, and a second component which comprises ethanol, and optionally a third component that is capable of inhibiting aldehyde dehydrogenase.
- 25 25. A therapeutic system or kit according to claim 24 in which the aldehyde producing portion is a catalytically active portion of alcohol dehydrogenase, the second component is ethanol and the third component is Disulfiram.
- 30 26. Human alcohol dehydrogenase or a catalytically active portion thereof for use in medicine.
27. Use of alcohol dehydrogenase or a catalytically active portion thereof in the manufacture of a medicament for the treatment of cancer.